Clinical characteristics of MPAL with distinct mutations
| . | PHF6 (n = 6) . | DNMT3A (n = 6) . | No PHF6 or DNMT3A (n = 14) . |
|---|---|---|---|
| Age, median (IQR), y | 26.5 (24.2-39.2) | 60.5 (54.5-62.8) | 40 (12-62.2) |
| Sex, M/F | 4/2 | 3/3 | 8/6 |
| Prior history | 1 (CHL) | 2 (lung cancer and HIV) | 1 (melanoma) |
| Extramedullary disease | 5 | 4 | 0 |
| BM involvement | 5 | 6 | 14 |
| CNS involvement | 2 | 1 | 5 |
| CBC at the diagnosis, median (IQR) | |||
| WBC, ×109/L | 7 (3-11.7) | 3 (1.8-28.8) | 31.7 (22.1-119.1) |
| ANC, ×109/L | 1.2 (0.6-2) | 0.4 (0.1-1.4) | 1.4 (0.4-1.9) |
| Hb, g/dL | 12.9 (12.2-13.2) | 10.7 (9.3-12.6) | 8.4 (7.4-9.5) |
| PLT, ×109/L | 219 (179-246.2) | 121.5 (64-258.5) | 79.5 (34-121.2) |
| Blasts, % | 35.5 (7.5-59) | 12.5 (0-40) | 51 (26-81.5) |
| BM blasts, % | 74.5 (55.8-79.8) | 80 (63.8-88.8) | 82.5 (73.8-89.2) |
| Immunophenotype | |||
| T-cell differentiation | 5 | 6 | 3 |
| Abnormal karyotype | 4 | 3 | 10 |
| Induction regimens, AML/ALL | 0/6 | 3/3 | 1/13 |
| Achieving CR1 | 4 | 5 | 13 |
| Allo-HSCT | 4 | 3 | 10 |
| Pre-HSCT MRD positivity | 2 | 3 | 4 |
| . | PHF6 (n = 6) . | DNMT3A (n = 6) . | No PHF6 or DNMT3A (n = 14) . |
|---|---|---|---|
| Age, median (IQR), y | 26.5 (24.2-39.2) | 60.5 (54.5-62.8) | 40 (12-62.2) |
| Sex, M/F | 4/2 | 3/3 | 8/6 |
| Prior history | 1 (CHL) | 2 (lung cancer and HIV) | 1 (melanoma) |
| Extramedullary disease | 5 | 4 | 0 |
| BM involvement | 5 | 6 | 14 |
| CNS involvement | 2 | 1 | 5 |
| CBC at the diagnosis, median (IQR) | |||
| WBC, ×109/L | 7 (3-11.7) | 3 (1.8-28.8) | 31.7 (22.1-119.1) |
| ANC, ×109/L | 1.2 (0.6-2) | 0.4 (0.1-1.4) | 1.4 (0.4-1.9) |
| Hb, g/dL | 12.9 (12.2-13.2) | 10.7 (9.3-12.6) | 8.4 (7.4-9.5) |
| PLT, ×109/L | 219 (179-246.2) | 121.5 (64-258.5) | 79.5 (34-121.2) |
| Blasts, % | 35.5 (7.5-59) | 12.5 (0-40) | 51 (26-81.5) |
| BM blasts, % | 74.5 (55.8-79.8) | 80 (63.8-88.8) | 82.5 (73.8-89.2) |
| Immunophenotype | |||
| T-cell differentiation | 5 | 6 | 3 |
| Abnormal karyotype | 4 | 3 | 10 |
| Induction regimens, AML/ALL | 0/6 | 3/3 | 1/13 |
| Achieving CR1 | 4 | 5 | 13 |
| Allo-HSCT | 4 | 3 | 10 |
| Pre-HSCT MRD positivity | 2 | 3 | 4 |
CHL, classical Hodgkin lymphoma.